Opko Health Posts Data From COVID-19 Trial With Its Kidney Disease Treatment


OPKO Health Inc OPK has announced preliminary topline results from its Phase 2 trial with Rayaldee to treat mild-to-moderate COVID-19. 

  • This study builds on increasing medical evidence that vitamin D repletion therapy can mitigate the severity of upper respiratory tract infections and accelerate recovery from COVID-19.
  • By Day 7, mean serum 25D levels increased with Rayaldee treatment to 82 ng/mL and remained elevated for the trial duration, with 88% of subjects attaining the targeted level. 
  • In contrast, mean 25D declined slightly with placebo treatment.
  • Rayaldee is approved for treating secondary hyperparathyroidism in non-dialysis chronic kidney disease patients by raising 25D to levels as high as 100 ng/mL.
  • A second primary efficacy endpoint was the benefit of raising serum 25D on time to resolution of five COVID-19 symptoms. 
  • The three symptoms related to respiratory function resolved more quickly when serum 25D was elevated at Days 7 and 14, with the resolution of chest congestion occurring 3.4 days sooner. 
  • The mean time to resolution for all five symptoms was not significantly different between the treatment groups since symptoms unrelated to respiratory function were unresponsive to treatment.  
  • Price Action: OPK shares are up 4.01% at $4.80 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!